Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Shares of health insurance company Humana (NYSE:HUM)
jumped 4.9% in the morning session after the company reported better-than-expected second-quarter results and raised its full-year financial guidance. The health insurer lifted its forecast for full-year adjusted earnings to approximately $17 per share, up from a prior estimate of about $16.25 and surpassing analysts' projections. Humana also increased its annual revenue guidance to at least $128 billion. Adding to the positive news, the company signaled that its decline in Medicare Advantage membership would be less severe than previously feared, forecasting a loss of up to 500,000 members instead of 550,000. This strong report and optimistic outlook provided a notable contrast to the more disappointing guidance recently issued by some of its peers in the health insurance sector, boosting investor confidence.
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its price target to $42 from $36. The upgrade followed positive developments in the company's planned acquisition of Sage Therapeutics. Supernus announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the deal had expired. The expiration of this period, a requirement for major mergers and acquisitions in the U.S., removed a key regulatory hurdle, allowing the transaction to proceed. The tender offer for Sage shares was set to expire on July 30, 2025, after which Supernus planned to complete the merger. This acquisition was expected to enhance Supernus's product portfolio with Sage's innovative treatments, a move that likely bolstered analyst confidence.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Health insurance company Humana (NYSE:HUM) announced better-than-expected revenue in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its GAAP profit of $4.51 per share was 24% below analysts’ consensus estimates.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its full-year financial guidance, sparking a selloff.
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN)
jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its full-year guidance. The life sciences company announced that its revenue climbed 15% year-over-year to $182 million, driven by growth across all its franchises and geographies. Profitability also saw a substantial increase, with net income rising to $14.87 million from $5.71 million in the same quarter last year. A key indicator of future performance, company orders, grew by over 20%. Buoyed by these strong results, Repligen lifted its full-year 2025 revenue forecast to a range of $715 million to $735 million.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative sentiment was partly fueled by health insurance giant UnitedHealth Group, which reported a miss on its second-quarter earnings and issued a profit warning, casting a pall over the entire sector. More directly, NeoGenomics, a company also operating in the cancer diagnostics space, reported that it had missed its second-quarter sales targets. This news, which sent NeoGenomics' stock down significantly, suggested a potentially more challenging market environment for companies involved in oncology diagnostics, a core business for Myriad Genetics.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 7.6% in the afternoon session after the company lowered its full-year profit forecast, which overshadowed its second-quarter earnings and revenue beat. Despite reporting second-quarter revenue of $720 million and an adjusted earnings per share (EPS) of $1.18, both of which surpassed analyst expectations, investors focused on the weaker outlook. Revvity trimmed its full-year adjusted EPS guidance to a range of $4.85 to $4.95. This revision was driven by multiple headwinds, including a double-digit decline in its diagnostics revenue from China, a key international market. The company also faced shrinking profitability, as both its adjusted operating and gross margins fell compared to the previous year. Management also pointed to potential costs related to tariffs.
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
fell 3.7% in the morning session after the company extended a recent losing streak amid investor anxiety ahead of its second-quarter earnings announcement.
Shares of health coverage company Centene (NYSE:CNC)
jumped 5.9% in the afternoon session after the company reported second-quarter results that missed earnings estimates, but the stock rallied as investors looked past the disappointment as sales came in ahead of expectations.
Shares of medical technology company Integer Holdings (NYSE:ITGR)
fell 8.3% in the afternoon session after the company reported second-quarter results that featured a slight miss on a key profitability metric, which overshadowed a revenue beat and raised profit guidance.
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST)
jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook.
